¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå ¼ºÀå°ú µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 1,506¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 11.43%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2020³â »ó¹Ý±â¿¡´Â ½ÃÀå ¼ºÀåÀÌ Á¤Ã¼µÇ¾úÁö¸¸, 2020³â ¸»¿¡´Â ȸº¹¼¼·Î µ¹¾Æ¼¹½À´Ï´Ù. ÀÌ´Â ÁÖ·Î COVID-19 Ä¡·á¿¡ ´ÜÀ§ ¿ë·®ÀÌ »ç¿ëµÇ¸é¼ µ¿ÀÏÇÑ º´¿¡¼ ¿ë·®À» Ãë±ÞÇϰųª ÁÖÀÔÇÒ ¶§ À§ÇèÀÌ °¨¼ÒÇ߱⠶§¹®ÀÔ´Ï´Ù.
´ÜÀ§ ¿ë·® Á¦Á¦´Â ¾à¹°À» ½±°Ô ½Äº°ÇÒ ¼ö ÀÖ°í, Åõ¾à ½Ã±îÁö ¾à¹°ÀÇ Á¦ÇüÀ» º¸È£ÇÒ ¼ö ÀÖ´Ù´Â ¸¹Àº ÀåÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¿ë±â°¡ ¼Õ»óµÇÁö ¾Ê°í ¾à¹°ÀÌ »ç¿ëµÇÁö ¾ÊÀº °æ¿ì, Á¦Á¦¸¦ º¯°æÇÏÁö ¾Ê°í Àçó¹æ ¹× ȸ¼öÇÒ ¼ö ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ÀåÁ¡Àº ÀûÀýÇÑ ¾çÀ» Åõ¿©ÇÒ ¼ö ÀÖ°í ȯÀÚ°¡ ±ÔÁ¤µÈ Çѵµ¸¦ ÃʰúÇÏÁö ¾Êµµ·Ï ÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù.
±×·¯³ª COVID-19 ÆÒµ¥¹ÍÀº ÀǾàǰ ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀÇ Àü¹Ý±â¿¡ ¼ºÀåÀÌ µÐȵǾúÁö¸¸ 2020³â ¸»ºÎÅÍ ½ÃÀåÀÌ È¸º¹µÇ±â ½ÃÀÛÇß½À´Ï´Ù. ´ÜÀ§ ¿ë·® Á¦Á¶´Â Ãë±Þ ¹× ¿À¿° À§ÇèÀ» ÁÙÀ̱â À§ÇØ ÇöÀç ½Ã³ª¸®¿À¿¡¼ À¯¸®ÇÏ°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ÜÀ§ ¿ë·®Àº °ø±â °¨¿°À̳ª Á÷Á¢ Á¢ÃËÀ¸·Î ÀÎÇÑ ¹ÙÀÌ·¯½º °¨¿° °¡´É¼ºÀ» ¹èÁ¦ÇÏ¿© ȯÀÚ¿Í ÀÇ·á Á¾»çÀÚ ¸ðµÎ¸¦ º¸È£Çϱâ À§ÇØ COVID-19 ȯÀÚ¸¦ À§ÇÑ º´¿ø¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù.
´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- Á¶´Þ ¹æ½Äº°·Î´Â ¾Æ¿ô¼Ò½Ì ºÎ¹®ÀÌ 2024³â ¸ÅÃâ ½ÃÀå Á¡À¯À² 60.74%·Î °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ¾Æ¿ô¼Ò½Ì ¼ºñ½º´Â ºñ¿ë È¿À²¼º, Àü¹®¼º, À¯¿¬¼º, À§Çè °¨¼Ò, ¼¼°è ½ÃÀå Á¢±Ù¼º µîÀÇ ÀÌÀ¯·Î ´ÜÀ§ ¿ë·® Á¦Á¶ »ê¾÷À» Áö¹èÇß½À´Ï´Ù.
- °íü ´ÜÀ§ ¿ë·® ºÎ¹®Àº 2024³â 50.49%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. Á¤Á¦ ¹× ĸ½¶°ú °°Àº °íü ´ÜÀ§ ¿ë·® Á¦ÇüÀº ³ôÀº ¼ö¿ä, ±¤¹üÀ§ÇÑ ÀÀ¿ë ºÐ¾ß ¹× ȯÀÚÀÇ ÆíÀǼºÀ¸·Î ÀÎÇØ ´ÜÀ§ ¿ë·® ¸¶ÄÉÆÃÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â µ¶¸³ ¾à±¹ ºÎ¹®ÀÌ 2024³â 39.11%ÀÇ ÃÖ´ë ¸ÅÃâ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇßÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
- ºÏ¹Ì´Â 2024³â 37.73%ÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²·Î ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀåÀ» Áö¹èÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ³ôÀº ÀÇ·á ÀÎÇÁ¶ó, ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü, ȯÀÚ ¾ÈÀü°ú Åõ¾àÀÇ Á¤È®¼º¿¡ ÃÊÁ¡À» ¸ÂÃá °·ÂÇÑ ±ÔÁ¦°¡ ½ÃÀå ¼öÀÍÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå ºÐ¼® ¹æ¹ý¡¤¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå ¿¬°ü Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ±â¼ú »óȲ
- °¡°Ý ¸ðµ¨ ºÐ¼®
- ½ÃÀå ºÐ¼® Åø
- Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : Á¶´Þ ¹æ¹ýº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : Á¶´Þ ¹æ¹ýº° º¯µ¿ ºÐ¼®
- Á¶´Þóº°(2018-2030³â)
- »ç³»
- ¾Æ¿ô¼Ò½Ì
Á¦5Àå ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : Á¦Ç°º° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : Á¦Ç°º° º¯µ¿ ºÐ¼®
- Á¦Ç°º°(2018-2030³â)
- ¾×ü ´ÜÀ§ ¿ë·®
- °íÇü ´ÜÀ§ ¿ë·®
- ±âŸ
Á¦6Àå ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ºÎ¹® ´ë½Ãº¸µå
- ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
- ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
- µ¶¸³ ¾à±¹
- Àå±â°£º´ ½Ã¼³
- º´¿ø
- ±âŸ
Á¦7Àå ´ÜÀ§ ¿ë·® Á¦Á¶ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ½ÃÀå Á¡À¯À² ºÐ¼® : Áö¿ªº°(2024³â¡¤2030³â)
- ½ÃÀå ´ë½Ãº¸µå : Áö¿ªº°
- ¼¼°è ½ÃÀå ÇöȲ : Áö¿ªº°
- ºÏ¹Ì
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø,
- ¹Ì±¹
- ij³ª´Ù
- ¸ß½ÃÄÚ
- À¯·´
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø,
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- µ§¸¶Å©
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø,
- ÀϺ»
- Áß±¹
- Àεµ
- ű¹
- Çѱ¹
- È£ÁÖ
- ¶óƾ¾Æ¸Þ¸®Ä«
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø,
- ºê¶óÁú
- ¾Æ¸£ÇîÆ¼³ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ½ÃÀå ÃßÁ¤°ú ¿¹Ãø,
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- Äí¿þÀÌÆ®
Á¦8Àå °æÀï ±¸µµ
- ±â¾÷ ºÐ·ù
- ±â¾÷ ½ÃÀå »óȲ ºÐ¼®, 2024³â(±â¾÷ È÷Æ®¸Ê ºÐ¼®)
- ±â¾÷ °³¿ä
- Catalent Inc.
- Unither Pharmaceuticals
- Thermo Fisher Scientific
- Corden Pharma
- Mikart
- Tape Mark
- Renaissance Lakewood LLC
- Medical Packaging Inc
- American Health Packaging
- PCI Pharma Services
- Amcor PLC
- Bristol-Myers Squibb
- AbbVie Inc.
- Merck &Co. Inc.
- Pfizer Inc.
ksm 25.03.17
Unit Dose Manufacturing Market Growth & Trends:
The global unit dose manufacturing market size is expected to reach USD 150.61 billion by 2030, registering a CAGR of 11.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. In the first half of 2020, the growth of the market was stagnant, but the market started to recover by the end of 2020. It was mainly due to the use of unit doses for the treatment of COVID-19 as it decreases the risk involved while handling and pouring doses from the same bottle.
Unit dose manufacturing has many advantages as the drug can be easily identified, and the formulation of the drug is protected until the moment of administration. If the container is intact and the drug has not been used, it can be redisposed and retrieved without changing its formulation. The most important benefit is that it can be administered in the proper dosage and ensures that the patient does not exceed the prescribed limit.
However, the COVID-19 pandemic has a significant effect on the pharmaceutical market. The first half of the COVID-19 pandemic had slowed growth but by the end of 2020, the market started to recover. The unit dose manufacturing is lucratively used in the current scenario as it reduces the risk of handling and contamination. Also, unit doses are widely used in hospitals for COVID-19 patients to safeguard both patients and healthcare personnel to eliminate the possibility of viral transmission by airborne transmission or direct touch.
Unit Dose Manufacturing Market Report Highlights:
- By sourcing, the outsourcing segment led the market with the largest revenue market share of 60.74% in 2024. Outsourcing services dominated the unit dose manufacturing industry, owing to cost-effectiveness, expertise, flexibility, risk reduction, and access to global markets.
- The solid unit dose segment led the market with the largest revenue share of 50.49% in 2024. Solid unit dosage forms such as tablets and capsules dominate unit dose marketing due to their high demand, widespread applications, and patient convenience.
- Based on end use, the independent pharmacies segment led the market with the largest revenue share of 39.11% in 2024 and is also anticipated to register at the fastest CAGR over the forecast period.
- North America dominated the unit dose manufacturing market with the largest revenue share of 37.73% in 2024. The market revenue growth is driven by the region's advanced healthcare infrastructure, high prevalence of chronic diseases, and strong regulatory focus on patient safety and medication accuracy.
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Regional Scope
- 1.1.2. Estimates And Forecast Timeline
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased Database
- 1.4.2. GVR's Internal Database
- 1.4.3. Secondary Sources
- 1.4.4. Primary Research
- 1.5. Information Or Data Analysis
- 1.5.1. Data Analysis Models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity Flow Analysis
- 1.7.2. Parent Market Analysis
- 1.8. List Of Secondary Sources
- 1.9. List Of Abbreviations
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Unit Dose Manufacturing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increased Adoption of Unit Doses
- 3.2.1.2. Benefits of Manufacturing Unit Doses Over Repackaging
- 3.2.1.3. Growing Outsourcing Activities
- 3.2.1.4. Technological Advancements in Unit Dose Manufacturing
- 3.2.1.5. Increasing Prevalence of Chronic Diseases and Demand for Personalized Medicine
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Challenges Associated with the Adoption of Manufactured Unit Doses
- 3.2.2.2. Compliance Issues with Outsourcing
- 3.3. Technology Landscape
- 3.4. Pricing Model Analysis
- 3.5. Market Analysis Tools
- 3.5.1. Porter's Five Forces Analysis
- 3.5.2. PESTEL Analysis
- 3.5.3. COVID-19 Impact Analysis
Chapter 4. Unit Dose Manufacturing Market: Sourcing Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Unit Dose Manufacturing Market: Sourcing Movement Analysis
- 4.3. Unit Dose Manufacturing Market Estimates & Forecasts, by Sourcing, 2018 - 2030 (USD Million)
- 4.4. In-House
- 4.4.1. In-House Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 4.5. Outsourcing
- 4.5.1. Outsourcing Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Unit Dose Manufacturing Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Unit Dose Manufacturing Market: Product Movement Analysis
- 5.3. Unit Dose Manufacturing Market Estimates & Forecasts, by Product, 2018 - 2030 (USD Million)
- 5.4. Liquid Unit Dose
- 5.4.1. Liquid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 5.5. Solid Unit Dose
- 5.5.1. Solid Unit Dose Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Unit Dose Manufacturing Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Unit Dose Manufacturing Market: End Use Movement Analysis
- 6.3. Unit Dose Manufacturing Market Estimates & Forecasts, by End Use, 2018 - 2030 (USD Million)
- 6.4. Independent Pharmacies
- 6.4.1. Independent Pharmacies Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 6.5. Long Term Care Facility
- 6.5.1. Long Term Care Facility Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 6.6. Hospitals
- 6.6.1. Hospitals Market Estimates & Forecasts, 2018 - 2030 (USD Million)
- 6.7. Others
- 6.7.1. Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Unit Dose Manufacturing Market: Regional Estimates & Trend Analysis
- 7.1. Regional Market Share Analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. North America
- 7.4.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Sweden
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Thailand
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Australia
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. MEA
- 7.8.1. Market Estimates and Forecast, (Revenue, USD Million, 2018 - 2030)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
- 8.2. Company Market Position Analysis, 2024 (Company Heat Map Analysis)
- 8.3. Company Profiles
- 8.3.1. Catalent Inc.
- 8.3.1.1. Company Overview
- 8.3.1.2. Financial Performance
- 8.3.1.3. Service Benchmarking
- 8.3.1.4. Strategic Initiatives
- 8.3.2. Unither Pharmaceuticals
- 8.3.2.1. Company Overview
- 8.3.2.2. Financial Performance
- 8.3.2.3. Service Benchmarking
- 8.3.2.4. Strategic Initiatives
- 8.3.3. Thermo Fisher Scientific
- 8.3.3.1. Company Overview
- 8.3.3.2. Financial Performance
- 8.3.3.3. Service Benchmarking
- 8.3.3.4. Strategic Initiatives
- 8.3.4. Corden Pharma
- 8.3.4.1. Company Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Service Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. Mikart
- 8.3.5.1. Company Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Service Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. Tape Mark
- 8.3.6.1. Company Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Service Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. Renaissance Lakewood LLC
- 8.3.7.1. Company Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Service Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. Medical Packaging Inc
- 8.3.8.1. Company Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Service Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.3.9. American Health Packaging
- 8.3.9.1. Company Overview
- 8.3.9.2. Financial Performance
- 8.3.9.3. Service Benchmarking
- 8.3.9.4. Strategic Initiatives
- 8.3.10. PCI Pharma Services
- 8.3.10.1. Company Overview
- 8.3.10.2. Financial Performance
- 8.3.10.3. Service Benchmarking
- 8.3.10.4. Strategic Initiatives
- 8.3.11. Amcor PLC
- 8.3.11.1. Company Overview
- 8.3.11.2. Financial Performance
- 8.3.11.3. Service Benchmarking
- 8.3.11.4. Strategic Initiatives
- 8.3.12. Bristol-Myers Squibb
- 8.3.12.1. Company Overview
- 8.3.12.2. Financial Performance
- 8.3.12.3. Service Benchmarking
- 8.3.12.4. Strategic Initiatives
- 8.3.13. AbbVie Inc.
- 8.3.13.1. Company Overview
- 8.3.13.2. Financial Performance
- 8.3.13.3. Service Benchmarking
- 8.3.13.4. Strategic Initiatives
- 8.3.14. Merck & Co. Inc.
- 8.3.14.1. Company Overview
- 8.3.14.2. Financial Performance
- 8.3.14.3. Service Benchmarking
- 8.3.14.4. Strategic Initiatives
- 8.3.15. Pfizer Inc.
- 8.3.15.1. Company Overview
- 8.3.15.2. Financial Performance
- 8.3.15.3. Service Benchmarking
- 8.3.15.4. Strategic Initiatives